NasdaqGM:URGNBiotechs
UroGen Pharma (URGN) Stock Looks Overvalued As 257% Returns Raise The Bar
UroGen Pharma stock has delivered very strong share price gains in recent years, yet the current market multiples lean toward an overvalued reading and the broader valuation checks do not point to a clear bargain.
Over the past 3 years, UroGen Pharma has returned 256.6%, which puts extra focus on whether recent optimism is already well reflected in the price.
Future revenue growth from its approved and late stage products can support the current valuation, but ongoing development costs and...